Last reviewed · How we verify
anesthesics plus antiinflammatory, CLIFE1 — Competitive Intelligence Brief
marketed
Pain Management / Anesthesia
Small molecule
Live · refreshed every 30 min
Target snapshot
anesthesics plus antiinflammatory, CLIFE1 (anesthesics plus antiinflammatory, CLIFE1) — Hospital de Viladecans. CLIFE1 combines anesthetic and anti-inflammatory properties to provide pain relief and reduce inflammatory responses simultaneously.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anesthesics plus antiinflammatory, CLIFE1 TARGET | anesthesics plus antiinflammatory, CLIFE1 | Hospital de Viladecans | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anesthesics plus antiinflammatory, CLIFE1 CI watch — RSS
- anesthesics plus antiinflammatory, CLIFE1 CI watch — Atom
- anesthesics plus antiinflammatory, CLIFE1 CI watch — JSON
- anesthesics plus antiinflammatory, CLIFE1 alone — RSS
Cite this brief
Drug Landscape (2026). anesthesics plus antiinflammatory, CLIFE1 — Competitive Intelligence Brief. https://druglandscape.com/ci/anesthesics-plus-antiinflammatory-clife1. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab